Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis

被引：0
|
作者：
Simpson, Eric [1 ]
Boguniewicz, Mark [2 ,3 ]
Eichenfield, Lawrence [4 ]
Gonzales, Mercedes E. [5 ]
Hebert, Adelaide A. [6 ]
Prajapati, Vimal H. [7 ,8 ]
Gooderham, Melinda [9 ,10 ]
Krupa, David [11 ]
Chu, David H. [11 ]
Higham, Robert C. [11 ]
Berk, David R. [11 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR USA
[2] Natl Jewish Hlth, Denver, CO USA
[3] Univ Colorado, Sch Med, Aurora, CO USA
[4] Univ Calif San Diego, Radys Childrens Hosp San Diego, San Diego, CA USA
[5] Pediat Skin Res LLC, Miami, FL USA
[6] UT Hlth, McGovern Med Sch, Houston, TX USA
[7] Skin Hlth Wellness Ctr, Dermatol Res Inst & Prob Med Res, Calgary, AB, Canada
[8] Univ Calgary, Calgary, AB, Canada
[9] SKiN Ctr Dermatol, Prob Med Res, Peterborough, ON, Canada
[10] Queens Univ, Peterborough, ON, Canada
[11] Arcutis Biotherapeut Inc, Westlake Village, CA USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
atopic dermatitis; efficacy; patient-reported outcomes; roflumilast cream; safety;
D O I：
10.1093/bjd/ljae266.022
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
641
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Efficacy and safety of ruxolitinib cream among adolescents with atopic dermatitis: Pooled Results from two phase 3 studies
    Eichenfield, Lawrence F.
    Simpson, Eric L.
    Siegfried, Elaine C.
    Kuligowski, Michael E.
    Venturanza, May E.
    Sun, Kang
    Paller, Amy S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB158 - AB158
  • [12] Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials
    Igarashi, Atsuyuki
    Tsuji, Gaku
    Fukasawa, Shuichi
    Murata, Ryusei
    Yamane, Satoshi
    JOURNAL OF DERMATOLOGY, 2024, 51 (11): : 1404 - 1413
  • [13] Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial
    Simpson, Eric L.
    Eichenfield, Lawrence F.
    Papp, Kim A.
    Forman, Seth B.
    Hebert, Adelaide A.
    Gonzalez, Mercedes E.
    Gooderham, Melinda J.
    Hong, H. Chih-ho
    Prajapati, Vimal H.
    Guttman-Yassky, Emma
    Silverberg, Jonathan I.
    Seal, Melissa S.
    Krupa, David
    Almaraz, Erin
    Hanna, Diane
    Burnett, Patrick
    Snyder, Scott
    Chu, David H.
    Higham, Robert C.
    Berk, David R.
    DERMATITIS, 2025,
  • [14] Long-term safety and efficacy of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis: a 52-week, phase 3, open-label extension trial
    Simpson, Eric L.
    Eichenfield, Lawrence F.
    Papp, Kim A.
    Forman, Seth
    Hebert, Adelaide A.
    Gonzalez, Mercedes E.
    Gooderham, Melinda
    Hong, H. Chih-ho
    Prajapati, Vimal H.
    Guttman, Emma
    Silverberg, Jonathan
    Seal, Melissa
    Krupa, David
    Burnett, Patrick
    Synder, Scott
    Chu, David H.
    Higham, Robert C.
    Berk, David R.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 20 - 20
  • [15] Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
    Simpson, Eric L.
    Prajapati, Vimal H.
    Leshem, Yael A.
    Chovatiya, Raj
    de Bruin-Weller, Marjolein S.
    Staender, Sonja
    Pink, Andrew E.
    Calimlim, Brian M.
    Lee, Wan-Ju
    Teixeira, Henrique
    Ladizinski, Barry
    Hu, Xiaofei
    Yang, Yang
    Liu, Yingyi
    Liu, Meng
    Grada, Ayman
    Platt, Andrew M.
    Silverberg, Jonathan I.
    DERMATOLOGY AND THERAPY, 2024, 14 (05) : 1127 - 1144
  • [16] Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis
    Thyssen, J. P.
    Yosipovitch, G.
    Paul, C.
    Kwatra, S. G.
    Chu, C. Y.
    DiBonaventura, M.
    Feeney, C.
    Zhang, F.
    Myers, D.
    Rojo, R.
    Valdez, H.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (03) : 434 - 443
  • [17] Dupilumab Improves Patient-Reported Outcomes (PROs) in a Phase 2 Study in Adults with Moderate-to-Severe Atopic Dermatitis
    Simpson, Eric
    Worm, Margitta
    Soong, Weily
    Blauvelt, Andrew
    Eckert, Laurent
    Wu, Richard
    Ardeleanu, Marius
    Graham, Neil
    Pirozzi, Gianluca
    Sutherland, E. Rand
    Mastey, Vera
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB167 - AB167
  • [18] Tapinarof cream 1% once daily for plaque psoriasis: Patient-reported outcomes from two pivotal phase 3 trials
    Bissonnette, Robert
    Strober, Bruce
    Lebwohl, Mark
    Bagel, Jerry
    Del Rosso, James
    Merola, Joseph F.
    Bhatia, Neal
    Yamauchi, Paul
    Brown, Philip M.
    Rubenstein, David S.
    Tallman, Anna M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB71 - AB71
  • [19] Effects of ruxolitinib cream on patient-reported quality of life in atopic dermatitis: 52-week pooled results from two phase III studies
    Simpson, Eric L.
    Silverberg, Jonathan I.
    Armstrong, April W.
    Fuxench, Zelma C. Chiesa
    Venturanza, May E.
    Kallender, Howard
    Gao, Jessy
    Kircik, Leon
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E122 - E123
  • [20] Achieving a deep response on patient-reported outcomes with upadacitinib in patients with moderate to severe atopic dermatitis: Results from three phase 3 trials
    Chovatiya, Raj
    Schuttelaar, Marie-Louise
    Calimlim, Brian
    Liu, Yingyi
    Takemoto, Shunya
    Staender, Sonja
    CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (08): : 1017 - 1018
12345